Opinion: CMS needs to do FDA’s job and limit the use of Biogen’s pricey new Alzheimer’s drug

Now that the FDA has approved Biogen’s expensive new Alzheimer’s drug with little clinical benefit potential, but plenty of potential to speed the bankruptcy of the government’s health care program for seniors, it’ll be up to the Centers for Medicare and Medicaid Services to limit payment for it and...

Click to view original post